Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$2.24M+596.27%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Marvin L. Slosman
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 127
- Beta
- 0.91
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -15.13
Financials
Revenue
$2.24M+596.3%Net Income
$-9.76MEBITDA
$-9.76MFree Cash Flow
$-10.88MEPS (diluted)
$-0.12Shares Outstanding (diluted)
85.62M+152885976.8%Operating Expenses
$9.12MCash & Debt
$19.25MReturn of Capital
$0.00Revenue by Segment (annual)
$5.17MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $8.98M | $-48.79M | $-0.76 |
| 2024 | $7.01M | $-32.01M | $-0.76 |
| 2023 | $6.21M | $-19.92M | $-0.82 |
| 2022 | $5.17M | $-18.49M | $-2.35 |
| 2021 | $4.50M | $-14.92M | $-2.03 |
| 2020 | $2.48M | $-10.54M | $-6.90 |
| 2019 | $3.72M | $-10.04M | $-72.00 |
| 2018 | $3.60M | $-7.24M | $-247.50 |
| 2017 | $2.76M | $-8.44M | $-4265.93 |
| 2016 | $1.89M | $-8.46M | $-151089.29 |
| 2015 | $2.31M | $-15.59M | $-1416818.18 |
| 2014 | $2.82M | $-25.09M | $-4182500.00 |
| 2013 | $4.87M | $-29.26M | $-5851600.00 |
| 2012 | $5.35M | $-17.60M | $-9217.92 |
Valuation
NSPRhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-30.00%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·4d ago·Negative
… CGuard Prime stent platform to include transcarotid artery revascularization (“TCAR”) procedures – MIAMI, Nov. 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime Carotid Stent for the prevention of stroke, today announced the successful completion of the first U.S. commercial transcarotid artery revascularization (“TCAR”) procedures utilizing its CGuard® Prime TransCarotid Stent System, following U.S. Food and Drug Administ…
View source ↗ - Newszacks.com·5d ago·Positive
InspireMD (NSPR) Upgraded to Buy: Here's Why InspireMD (NSPR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsglobenewswire.com·9d ago·Negative
InspireMD Announces Pricing of $37.5 Million Public Offering MIAMI, Nov. 13, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the pricing of its previously announced underwritten public offering of (i) 7,342,308 shares of its common stock, (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase 50,350,000 shares of its common stock, a…
View source ↗ - Newsglobenewswire.com·62d ago·Neutral
InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million - Amendments align trigger event of existing warrants with anticipated FDA approval of CGuard Prime 80 cm, which the Company continues to anticipate in Q4 2026 -
View source ↗ - Newsglobenewswire.com·79d ago·Neutral
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MIAMI, Sept. 04, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to a new non-executive employee in the aggregate amount of 23,764 shares of restricted stock (the “Inducement Grants”) outside of…
View source ↗ - Newsglobenewswire.com·80d ago·Neutral
InspireMD to Participate in Upcoming H.C. Wainwright 28th Annual Global Investment Conference MIAMI, Sept. 03, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming H.C.
View source ↗ - Newsseekingalpha.com·97d ago·Positive
InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript InspireMD, Inc. (NSPR) Q2 2026 Earnings Call Transcript
View source ↗ - Newsglobenewswire.com·97d ago·Neutral
… Financial Results - Company to host investor conference call today, August 17 th , at 8:30am EDT - MIAMI, Aug. 17, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the three and six months ended June 30, 2026. Recent Business Highlights: Generated revenue of $1.8 million in the second quarter of 2026, in line with the second…
View source ↗
Earnings
Wed, Mar 17(in 4 months)
Consensus estimate $-0.11 per share
Typical surprise +15.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.11 vs $-0.15beat
- Mon, Aug 17$-0.17 vs $-0.20beat
- Mon, May 4$-0.16 vs $-0.19beat
- Wed, Mar 18$-0.14 vs $-0.22beat
- Tue, Nov 4$-0.17 vs $-0.17beat
- Mon, Aug 4$-0.26 vs $-0.24miss
Estimates and results for NSPR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by NSPR officers and directors.
- Bought
- $1.5m
- Sold
- $289k
29 trades
24 trades
- Stuka Paulbought
- Stuka Paulbought
- Lawless Michael Abought
- Lawless Michael Abought
- Berman Michaelbought
- Berman Michaelbought
- Slosman Marvinbought
- Slosman Marvinbought
47 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in NSPR.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
